Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04858724
Recruiting Observational

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

NCT04858724 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Observational
Started
2020-12-01
Last updated
2026-08-18

Condition(s) studied

IgA Nephropathy

Study summary

1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research.
2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis.
3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation.
4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. No age limit, no gender limit; 2. Kidney biopsy confirmed primary IgA nephropathy; 3. Sign the informed consent form voluntarily Exclusion Criteria: 1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura; 2. IgAN is clinically diagnosed but not confirmed by pathology; 3. The patient refuses to participate; 4. Patients judged by other investigators to be unsuitable for inclusion in the study.

Primary outcome measure(s)

  • The proportion of a decline in estimated glomerular filtration rate by > 50% from baseline — 1 year
    To evaluate the renal function
  • The proportion of doubling serum creatinine compared with baseline — 1 year
    To evaluate the renal function
  • Incidence of ESRD — 1 year
    To evaluate the renal function

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital, Shanghai JiaoTong University School of Medicine Shanghai Shanghai Municipality Recruiting

More Ruijin Hospital trials in China

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC Recruiting
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis Active, not recruiting
Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection Recruiting
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center Active, not recruiting
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer Recruiting

Other trials for the same condition

Atrasentan in Patients With IgA Nephropathy Active, not recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Recruiting
IgA Nephropathy Biomarkers Evaluation Study (INTEREST) Recruiting
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Starting soon
Nefecon and Ambrisentan in IgA Nephropathy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04858724 on ClinicalTrials.gov ↗ ← All trials in China